Document is current
Any future updates will be listed below
-
Authors
Pöschmann, Lea
Meier, Friedegund
Eichler, Martin
Gellrich, Frank Friedrich
Schmitt, Jochen
Schoffer, Olaf
-
Funding
Funding for this research was provided by:
Universitätsklinikum Carl Gustav Carus Dresden an der Technischen Universität Dresden
- License Information
-
More Information
Article History
Received: 26 February 2025
Accepted: 17 September 2025
First Online: 16 October 2025
Declarations
:
: The research involving human subjects was reviewed and approved by the ethics committee of TU Dresden, reference number: SR + BO-EK-184042023. Informed consent was obtained from all study participants in accordance with the principles of the Declaration of Helsinki.
: Not applicable.
: JS reports institutional grants for investigator-initiated research from the German Federal Joint Committee, German Ministry of Health, German Ministry of Research, European Union, German Federal State of Saxony, Novartis, Sanofi, ALK, and Pfizer. He participated in advisory board meetings as a paid consultant for Sanofi, Lilly, and ALK. Prof. Schmitt serves the German Ministry of Health as a member of the German National Council for Health and Care.Independently of this study, OS was a paid consultant for Novartis. He is also a member of the certification committee “Skin Cancer Centers” of the German Cancer Society and a member of the panel of experts for the project “Research into criteria to evaluate certificates and quality seals in accordance with Sec. 137a para. 3 sentence 2 No. 7 SGB V” for the Institute for Quality Assurance and Transparency in Healthcare (IQTIG).The other authors declare that they have no competing interests.
